148 related articles for article (PubMed ID: 23543294)
1. A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer.
Hata T; Fukunaga M; Murata K; Uemura Y; Fukuzaki T; Ota H; Ohue M; Ohnishi T; Tanaka N; Takemasa I; Mizushima T; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1657-63. PubMed ID: 23543294
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer.
Komatsu Y; Yuki S; Sogabe S; Fukushima H; Nakatsumi H; Kobayashi Y; Iwanaga I; Nakamura M; Hatanaka K; Miyagishima T; Kudo M; Munakata M; Meguro T; Tateyama M; Sakata Y
Acta Oncol; 2012 Sep; 51(7):867-72. PubMed ID: 22554343
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer.
Yamada Y; Yamaguchi T; Matsumoto H; Ichikawa Y; Goto A; Kato K; Hamaguchi T; Shimada Y
Invest New Drugs; 2012 Aug; 30(4):1690-6. PubMed ID: 21894500
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of irinotecan plus S-1 (IRIS) therapy to treat advanced/recurrent colorectal cancer.
Higashi D; Egawa Y; Hirano Y; Hirano K; Miyake T; Takahashi H; Uwatoko S; Abe S; Yamamoto S; Mikami K; Futami K; Maekawa T; Inoue R; Miyazaki M
Anticancer Res; 2014 Aug; 34(8):4595-9. PubMed ID: 25075105
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer.
Oh SY; Ju YT; Choi SK; Ha CY; Lee WS; Kim HG; Lee GW; Kwon HC; Kang JH
Invest New Drugs; 2011 Oct; 29(5):1050-6. PubMed ID: 20238142
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302).
Komatsu Y; Yuki S; Sogabe S; Fukushima H; Iwanaga I; Kudo M; Tateyama M; Meguro T; Uebayashi M; Saga A; Sakata Y; Asaka M
Oncology; 2011; 80(1-2):70-5. PubMed ID: 21659785
[TBL] [Abstract][Full Text] [Related]
8. S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).
Miyamoto Y; Tsuji A; Tanioka H; Maekawa S; Kawanaka H; Kitazono M; Oki E; Emi Y; Murakami H; Ogata Y; Saeki H; Shimokawa M; Natsugoe S; Akagi Y; Baba H; Maehara Y
Int J Clin Oncol; 2016 Aug; 21(4):705-712. PubMed ID: 26746689
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer.
Kusaba H; Esaki T; Futami K; Tanaka S; Fujishima H; Mitsugi K; Sakai K; Ariyama H; Tanaka R; Kinugawa N; Ueki T; Mibu R; Baba E; Nakano S; Akashi K
Cancer Sci; 2010 Dec; 101(12):2591-5. PubMed ID: 21077997
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
[TBL] [Abstract][Full Text] [Related]
11. Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review.
Winther SB; Zubcevic K; Qvortrup C; Vestermark LW; Jensen HA; Krogh M; Sorbye H; Pfeiffer P;
Acta Oncol; 2016 Jul; 55(7):881-5. PubMed ID: 27181284
[TBL] [Abstract][Full Text] [Related]
12. A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer.
Sadahiro S; Suzuki T; Tanaka A; Okada K; Saito G; Kamijo A
Oncology; 2015; 88(6):353-9. PubMed ID: 25592116
[TBL] [Abstract][Full Text] [Related]
13. Long-term results of a phase II study of S-1 plus irinotecan in metastatic colorectal cancer.
Iwasa S; Yamada Y; Kato K; Goto A; Honma Y; Hamaguchi T; Shimada Y
Anticancer Res; 2012 Sep; 32(9):4157-61. PubMed ID: 22993378
[TBL] [Abstract][Full Text] [Related]
14. Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer.
Takaoka T; Kimura T; Shimoyama R; Kawamoto S; Sakamoto K; Goda F; Miyamoto H; Negoro Y; Tsuji A; Yoshizaki K; Goji T; Kitamura S; Yano H; Okamoto K; Kimura M; Okahisa T; Muguruma N; Niitsu Y; Takayama T
Cancer Chemother Pharmacol; 2016 Aug; 78(2):397-403. PubMed ID: 27342247
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer.
Shiozawa M; Akaike M; Sugano N; Tsuchida K; Yamamoto N; Morinaga S
Cancer Chemother Pharmacol; 2010 Oct; 66(5):987-92. PubMed ID: 20623226
[TBL] [Abstract][Full Text] [Related]
16. Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.
Winther SB; Österlund P; Berglund Å; Glimelius B; Qvortrup C; Sorbye H; Pfeiffer P;
BMC Cancer; 2017 Aug; 17(1):548. PubMed ID: 28814275
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer.
Goto A; Yamada Y; Yasui H; Kato K; Hamaguchi T; Muro K; Shimada Y; Shirao K
Ann Oncol; 2006 Jun; 17(6):968-73. PubMed ID: 16603600
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402).
Sugimoto N; Fujitani K; Imamura H; Uedo N; Iijima S; Imano M; Shimokawa T; Kurokawa Y; Furukawa H; Goto M
Anticancer Res; 2014 Feb; 34(2):851-7. PubMed ID: 24511022
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II study of irinotecan and UFT for advanced or metastatic colorectal cancer.
Mibu R; Tanaka S; Futami K; Shimada K; Hotokezaka M; Nakahara S; Ichimiya H; Kido H; Hirano Y; Kashiwagi T; Eguchi T; Mitsuki K; Mizumoto K; Tanaka M
Anticancer Res; 2007; 27(4C):2673-7. PubMed ID: 17695431
[TBL] [Abstract][Full Text] [Related]
20. Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer.
Komatsu Y; Yuki S; Fuse N; Kato T; Miyagishima T; Kudo M; Kunieda Y; Tateyama M; Wakahama O; Meguro T; Sakata Y; Asaka M
Adv Ther; 2010 Jul; 27(7):483-92. PubMed ID: 20559897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]